Sold as Nelkarmi. Every FDA application for this active ingredient.
As of Nov 21, 2026, FDA lists 1 application for Neladalkib (sold as Nelkarmi), first approved Nov 17, 2026, with 1 new use approved and 0 published complete response letters.
| A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLCALK-positive NSCLC, ALK-Positive Lung Cancer ยท TRIANA Biomedicines, Inc. | Phase 1 / Phase 2 | Recruiting | Mar 24, 2026 |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNon-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive ยท Nuvalent Inc. | Phase 3 | Recruiting | Jan 9, 2025 |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)Locally Advanced Solid Tumor, Metastatic Solid Tumor ยท Nuvalent Inc. | Phase 1 / Phase 2 | Recruiting | May 20, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA